Literature DB >> 27009171

Pulmonary veno-occlusive disease.

David Montani1, Edmund M Lau2, Peter Dorfmüller3, Barbara Girerd1, Xavier Jaïs1, Laurent Savale1, Frederic Perros1, Esther Nossent3, Gilles Garcia1, Florence Parent1, Elie Fadel4, Florent Soubrier5, Olivier Sitbon1, Gérald Simonneau1, Marc Humbert6.   

Abstract

Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH) characterised by preferential remodelling of the pulmonary venules. In the current PH classification, PVOD and pulmonary capillary haemangiomatosis (PCH) are considered to be a common entity and represent varied expressions of the same disease. The recent discovery of biallelic mutations in the EIF2AK4 gene as the cause of heritable PVOD/PCH represents a major milestone in our understanding of the molecular pathogenesis of PVOD. Although PVOD and pulmonary arterial hypertension (PAH) share a similar clinical presentation, with features of severe precapillary PH, it is important to differentiate these two conditions as PVOD carries a worse prognosis and life-threatening pulmonary oedema may occur following the initiation of PAH therapy. An accurate diagnosis of PVOD based on noninvasive investigations is possible utilising oxygen parameters, low diffusing capacity for carbon monoxide and characteristic signs on high-resolution computed tomography of the chest. No evidence-based medical therapy exists for PVOD at present and lung transplantation remains the preferred definitive therapy for eligible patients.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27009171     DOI: 10.1183/13993003.00026-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  43 in total

1.  Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.

Authors:  M S Zinter; A Melton; A J Sabnis; C C Dvorak; B M Elicker; H M Nawaytou; R J Kameny; J R Fineman
Journal:  Leuk Lymphoma       Date:  2017-09-28

2.  Pulmonary Veno Occlusive Disease Presenting as Failure to Thrive.

Authors:  Divij Pasrija; Shilpi Gupta; Ryan Breuer; Jeffrey Herendeen
Journal:  Indian J Pediatr       Date:  2021-01-14       Impact factor: 1.967

Review 3.  [Interstitial processes of the lungs in childhood].

Authors:  H Popper
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 4.  Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).

Authors:  Soni S Pullamsetti; Frédéric Perros; Prakash Chelladurai; Jason Yuan; Kurt Stenmark
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

5.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

6.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

Review 7.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 8.  Pulmonary veno-occlusive disease: a probably underdiagnosed cause of pulmonary hypertension in systemic sclerosis.

Authors:  Ana Catarina Duarte; Ana Cordeiro; Maria José Loureiro; Filipa Ferreira
Journal:  Clin Rheumatol       Date:  2020-01-22       Impact factor: 2.980

9.  Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction.

Authors:  Ahmed U Fayyaz; William D Edwards; Joseph J Maleszewski; Ewa A Konik; Hilary M DuBrock; Barry A Borlaug; Robert P Frantz; Sarah M Jenkins; Margaret M Redfield
Journal:  Circulation       Date:  2017-12-15       Impact factor: 29.690

Review 10.  Molecular genetic framework underlying pulmonary arterial hypertension.

Authors:  Laura Southgate; Rajiv D Machado; Stefan Gräf; Nicholas W Morrell
Journal:  Nat Rev Cardiol       Date:  2019-08-12       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.